Wakamatsu demonstrated a greater FVC decline in a retrospective cohort of 89 IPF patients with increased serum KL-6 levels (≥1000 U/mL) during follow-up compared with patients with no KL-6 increase [63]. This evidence concerns the gene MUC1 and idiopathic pulmonary fibrosis.